Restasis

Primary Uses

Restasis is used to treat a specific type of chronic dry eye known as keratoconjunctivitis sicca. It is prescribed for patients who have decreased tear production believed to be caused by ocular inflammation.

How It Works for Dry Eye

The medication helps by:

• Increasing the eyes' natural ability to produce tears.
• Addressing underlying inflammation that prevents the tear glands from functioning properly.

It is important to note that Restasis is generally not used for patients whose dry eye is caused by certain other factors, such as the use of tear duct plugs or specific anti-inflammatory medications.

Mechanism of Action

Restasis contains cyclosporine, which belongs to a class of medications known as immunomodulators. In many cases of chronic dry eye, also known as keratoconjunctivitis sicca, the eyes do not produce enough tears because of ongoing inflammation in the tear glands and on the surface of the eye.

While the exact way the medication works is not fully understood, it is believed to function by:

• Lowering inflammation: The active ingredient helps suppress the immune response that causes swelling and irritation in the tear-producing tissues.
• Restoring tear production: By reducing this inflammation, the medication allows the tear glands to function more effectively, increasing the eyes' natural ability to stay moist.

It is important to note that Restasis is intended for patients whose tear production is suppressed specifically due to ocular inflammation. It may not increase tear production in patients who are already using topical anti-inflammatory drugs or those who have tear duct plugs.

Common Side Effects

The most frequent side effect of Restasis is a temporary burning sensation in the eye. Other common side effects may include:

• Eye redness
• Discharge or watery eyes
• Blurred vision
• Feeling as though something is in the eye
• Eye itching

Serious Side Effects

Although rare, some side effects require immediate medical attention. Contact a healthcare provider if you experience:

• Severe eye pain
• Swelling of the eyelids
• Signs of an allergic reaction, such as a rash, severe dizziness, or swelling of the face, tongue, or throat
• Difficulty breathing

Contamination and Eye Injury

To prevent eye injury and contamination of the medication, the tip of the single-use vial or multidose bottle should not touch the eye or any other surface.

Contact Lens Use

Restasis should not be administered while wearing contact lenses. If lenses are worn, they should be removed before using the drops and may be reinserted 15 minutes after the dose is applied. Additionally, contact lenses should generally not be worn if the eyes are red.

Active Eye Infections

The safety and effectiveness of this medication have not been established in patients with active eye infections, such as herpes keratitis.

Hypersensitivity

This medication is contraindicated in individuals with a known or suspected hypersensitivity to cyclosporine or any other components of the formulation.

Use in Specific Populations

• Pediatric Use: The safety and effectiveness of Restasis have not been established in children under the age of 16.
• Pregnancy and Breastfeeding: While systemic absorption is minimal following topical application, individuals who are pregnant or breastfeeding should discuss the potential risks and benefits with a healthcare provider.

Pregnancy

There are no adequate and well-controlled studies of Restasis in pregnant women. Clinical data on its use during pregnancy are limited. However, because the medication is applied topically to the eye, systemic absorption into the bloodstream is very low and often undetectable. This suggests that the risk of birth defects or miscarriage is likely minimal.

If you are pregnant or planning to become pregnant, discuss the potential risks and benefits of using this medication with your healthcare provider.

Breastfeeding

It is unknown if cyclosporine passes into human breast milk after being used as an eye drop. While the systemic absorption of Restasis is minimal, healthcare providers typically advise caution for nursing mothers. Decisions regarding the use of Restasis while breastfeeding should be made in consultation with a doctor to weigh the benefits of treatment against any potential risks to the infant.

Dosage Forms

Restasis (cyclosporine ophthalmic emulsion) is a topical medication for use in the eyes. It is available in two primary packaging options:

• Single-use vials: These are individual, preservative-free containers. Each vial is intended for a single application to one or both eyes. Once opened, the vial should be used immediately and any remaining liquid must be discarded.
• Multi-dose Preservative-Free (MDPF) bottle: This is a multi-dose bottle designed with a specialized tip that prevents contamination, allowing the emulsion to remain sterile without the use of preservatives.

Available Strengths

Restasis is supplied in a concentration of 0.05%.

FDA Approval and Indications

The U.S. Food and Drug Administration (FDA) approved Restasis (cyclosporine ophthalmic emulsion) 0.05% in 2002. It is indicated to increase tear production in patients whose tear production is presumed to be suppressed due to ocular inflammation associated with keratoconjunctivitis sicca, commonly known as chronic dry eye.

The medication is not expected to increase tear production in patients who are currently using topical anti-inflammatory drugs or those who have punctal plugs.

Generic Availability

In February 2022, the FDA approved the first generic version of Restasis (cyclosporine ophthalmic emulsion 0.05% single-use vials). Generic versions are required to meet the same standards for quality, strength, and purity as the brand-name product.

Regulatory Oversight

Restasis is available by prescription only. There are currently no boxed warnings or Risk Evaluation and Mitigation Strategy (REMS) programs required for this medication. The FDA continues to monitor the safety and efficacy of the drug through standard post-marketing surveillance.

Generic Availability

Generic versions of Restasis (cyclosporine 0.05% ophthalmic emulsion) are available. Choosing a generic medication is often a primary way to reduce out-of-pocket expenses, as generics are typically priced lower than brand-name drugs.

Insurance and Pharmacy Factors

Most insurance plans and Medicare Part D cover cyclosporine ophthalmic emulsion, though the specific copay or coinsurance amount depends on the plan's formulary. Additionally, prices can vary between different retail pharmacies and mail-order services.

Financial Assistance

Patients may be able to lower their costs through several programs:

• Manufacturer Savings Cards: The manufacturer may offer savings cards or coupons for eligible patients with commercial insurance to help reduce out-of-pocket costs.
• Patient Assistance Programs: Some programs provide medications at a lower cost or for free to individuals who meet specific income requirements and do not have insurance coverage.